Abera Bioscience AB (NGM:ABERA)
Sweden · Delayed Price · Currency is SEK 8.10
0.00 (0.00%)
At close: Sep 3, 2026
Abera Bioscience AB Market Cap
Abera Bioscience AB has a market cap or net worth of 166.04 million as of September 4, 2026. Its market cap has increased by 32.70% in one year.
Market Cap
166.04M
Enterprise Value
148.33M
Revenue
9.10M
Ranking
n/a
PE Ratio
n/a
Stock Price
8.10
ChartMarket Cap Chart
Since February 24, 2021, Abera Bioscience AB's market cap has increased from 115.59M to 166.04M, an increase of 43.65%. That is a compound annual growth rate of 6.77%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 3, 2026 | 166.04M | 32.37% |
| Dec 30, 2025 | 125.44M | 81.17% |
| Dec 30, 2024 | 69.24M | -7.23% |
| Dec 29, 2023 | 74.63M | 20.46% |
| Dec 30, 2022 | 61.96M | -64.21% |
| Dec 30, 2021 | 173.12M | 49.77% |
| Feb 24, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Xbrane Biopharma AB | 197.40M |
| Elicera Therapeutics AB | 177.52M |
| Alzinova AB | 163.73M |
| Diamyd Medical AB | 163.66M |
| Initiator Pharma | 158.13M |
| Xintela AB | 144.69M |
| NextCell Pharma AB | 136.50M |
| Active Biotech AB | 133.12M |